Executive summary of the European consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance
European consensus · 2026 · Europe
Source and licence
- Authors
- Ben Sprangers, Camille Cohen, Viviane Gnemmi et al.
- Title
- Executive summary of the European consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance
- Journal
- Clinical Kidney Journal, 2026
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC13284707
Licence statement of the original publication
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
We introduce the European Union consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance (MGRS), a generic term to describe kidney disorders caused by a non-malignant monoclonal immunoglobulin clone. There are many subtypes of MGRS, with AL-amyloidosis being most prevalent. The consensus report aims at providing guidance to clinicians, pathologists and laboratory specialists who take care of patients with a (suspected) diagnosis of MGRS. This executive summary provides a condensed overview of the most important aspects of the diagnosis and management of patients with MGRS. Consultation of expert centers is strongly advised. Although most patients will benefit from hematological, clone-directed therapy, treatment decisions must be individualized, in view of the heterogeneity of patients between and within the MGRS subtypes. The final chapter discusses kidney transplantation in patients with MGRS. The working group acknowledges that most advice is based on low-quality evidence. The full report provides the rationale and a detailed discussion of the available literature. This executive summary is an introduction, and not a substitute for the full consensus report.
Contents of the original publication
The section headings of the original.
- INTRODUCTION
- CHAPTER 1: MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE: DEFINITION, DIAGNOSIS AND GENERAL ASPECTS OF TREATMENT [1–8]
- CHAPTER 2: MONOCLONAL IMMUNOGLOBULIN–ASSOCIATED AMYLOIDOSIS [12–15]
- CHAPTERS 3–9: NON-AMYLOID MGRS SUBTYPES [16–19]
- CHAPTER 10: KIDNEY TRANSPLANTATION IN MGRS [20]
- CONCLUSION
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint